PharmaJet partners with Abnova to develop needle-free COVID-19 vaccine

PharmaJet Logo

Closely-held PharmaJet’s needle-free injection system will be used to deliver a SARS-CoV mRNA vaccine being developed by Abnova, the world’s largest antibody vaccine manufacturer.

“Our system has been found to improve the immune response of multiple RNA/DNA vaccines, in addition to its proven ease of administration in wide-scale immunization settings,” Chris Cappello, PharmaJet’s president and CEO, said in a statement.

Dr. Wilber Huang, Abnova’s president and CEO, said, “We have taken a major next step toward mRNA vaccine development against COVID-19 based on the specific gene sequences generating successful antibody response from our DNAx immune platform. We would like to complement the mRNA immunization with a needle-free platform to further augment the protective antibody response against COVID-19 with an impactful clinical outcome.”

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.